Nanopore PGx sequencing to star allele analysis pipeline

Thank you for your interest in long-read nanopore pharmacogenomic sequencing (PGx workflow).

Conventional microarray and short-read sequencing technologies have limited resolution for pharmacogenomic sequencing. Nanopore long-read sequencing technology overcomes these limitations by providing the ability to disambiguate pseudogene homology, detect and characterise complicated structural variants and gene-pseudogene conversions, and phase haplotypes.

Available resources on the Nanopore Community:
Oxford Nanopore Technologies plc. or its subsidiaries. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, Oxford, Oxfordshire, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies plc. or its subsidiaries, the Wheel icon, AmPORE-TB, ElysION, EPI2ME, Flongle, GridION, MinION, MinKNOW, PromethION, and TraxION are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries. Information contained herein may be protected by patents or patents pending of Oxford Nanopore Technologies plc. All other brands and names contained are the property of their respective owners. © 2008 - 2025 Oxford Nanopore Technologies plc. or its subsidiaries. or its subsidiaries plc. All rights reserved. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.

Our Privacy policy sets out how Oxford Nanopore handles your personal information, and your rights.